A shorter 2 week course of radiation for diffuse midline glioma
Official title: Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial tests giving radiation over 2 weeks instead of 6 weeks for people with diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary.
Read our full plain-language summary
What the trial team says
This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giving 2 weeks of radiation. This may determine if there is a difference in the outcome of the treatment, and most importantly, the patients' quality of life.
Key facts
- Registry number
- NCT05077735
- Stage of testing
- Phase 2
- Conditions studied
- Diffuse Midline Glioma, H3 K27M-Mutant
Where it is running
This trial lists 2 sites.
-
Arizona
- Mayo Clinic Hospital in Arizona (Phoenix)
-
Minnesota
- Mayo Clinic in Rochester (Rochester)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.